Elite Pharmaceuticals Reports Q2 2027 Revenue and Pipeline Results

With a fiscal quarter ending before its calendar year, Elite's earnings release offers investors a first look at how a small US generic drug manufacturer is navigating pricing and production...

Elite Pharmaceuticals, Inc. (Nasdaq: ELTP), a Northvale, New Jersey-based manufacturer of generic and specialty pharmaceutical products, held its fiscal second-quarter 2027 earnings call on November 13, 2026, according to a transcript published by Seeking Alpha. The call was led by Chairman, Chief Executive Officer, and President Nasrat Hakim, alongside Chief Financial Officer Carter Ward.

Elite Pharmaceuticals operates on a fiscal year that ends in March, meaning its Q2 2027 period covers the months of July through September 2026. That calendar offset means the company's results reflect summer-quarter supply chain and demand conditions in the US generic drug market.

The company focuses on the development and manufacture of controlled-release and immediate-release oral solid dosage forms, according to its public filings with the Securities and Exchange Commission. Its product portfolio includes several Schedule II controlled substances, which are subject to Drug Enforcement Administration production quotas set annually.

DEA aggregate production quotas for Schedule II substances directly cap how much volume Elite and similar manufacturers can produce in a given year. Any shortfall or reallocation in those quotas would appear as a revenue constraint in a company of Elite's size. The specific revenue figures from the November 13 call were not fully reproduced in the available transcript excerpt, and the complete financial tables were not included in the source material reviewed for this article. The full quarterly report on Form 10-Q, once filed with the SEC, will provide audited figures.

Elite is a micro-cap company. As of its most recent annual report filed with the SEC for fiscal year 2026, the company reported total revenues of approximately $14.7 million for the twelve months ended March 31, 2026, according to SEC EDGAR records. That scale places it among the smaller publicly traded pharmaceutical manufacturers in the United States.

The company's business model includes both internal product sales and contract manufacturing services for larger pharmaceutical companies, a structure that ties its revenue in part to the production decisions of its clients. Changes in client demand or contract renewals represent a primary variable in its quarterly results, though specific contract details are generally not disclosed publicly.

Hakim has led the company for more than a decade and has previously used earnings calls to address FDA inspection outcomes and manufacturing capacity utilization. Whether either topic was raised on the November 13 call is not determinable from the available excerpt. The full transcript, as published by Seeking Alpha, would contain those details.

For US investors evaluating small-cap pharmaceutical exposure, Elite's results carry relevance as a data point on how smaller generic manufacturers are absorbing input cost inflation, which the Bureau of Labor Statistics has tracked through its Producer Price Index for pharmaceutical preparation manufacturing. That index rose 4.2 percent year over year as of September 2026, according to BLS data.

The Federal Reserve's rate environment also bears on companies of Elite's size. Smaller manufacturers with limited access to capital markets face higher effective borrowing costs when the federal funds rate remains elevated. The Fed held its benchmark rate in the 4.25 to 4.50 percent range at its most recent meeting, as noted in the Federal Reserve's November 2026 policy statement. That level affects the cost of any revolving credit or working capital facilities a company like Elite might carry.

What would clarify the full picture of Elite's Q2 2027 performance is the Form 10-Q filing expected to follow the earnings call, which will include the income statement, balance sheet, and cash flow statement in full. That filing is required by the SEC within 40 calendar days of the fiscal quarter's close for smaller reporting companies, placing the deadline in mid-November 2026.